ライフサイエンスコーパス: influenza virus vaccine

1 y of a novel TLR 7/8 agonist R848-conjugated influenza virus vaccine.

2 d may be the key to developing a "universal" influenza virus vaccine.

3 This knowledge will aid development of a pan-influenza virus vaccine.

4 ent of a hemagglutinin stalk-based universal influenza virus vaccine.

5 red as an antigen for developing a universal influenza virus vaccine.

6 the potential to be utilized as a universal influenza virus vaccine.

7 tion, thus setting the stage for a universal influenza virus vaccine.

8 s revitalized efforts to develop a universal influenza virus vaccine.

9 irus and immunization with a live attenuated influenza virus vaccine.

10 uenza epidemics and pandemics by inactivated influenza virus vaccine.

11 oach offers a means of generating a bivalent influenza virus vaccine.

12 or individuals who received live attenuated influenza virus vaccine.

13 n mice vaccinated with inactivated trivalent influenza virus vaccine.

14 roach for the generation of a more universal influenza virus vaccine.

15 in the neonate in response to an inactivated influenza virus vaccine.

16 f piglets were immunized with an inactivated influenza virus vaccine.

17 rum and mucosal antibodies to an inactivated influenza virus vaccine.

18 bute to the further development of universal influenza virus vaccines.

19 ls, bringing us a step closer to "universal" influenza virus vaccines.

20 ded in order to improve the effectiveness of influenza virus vaccines.

21 r development as live attenuated H2 pandemic influenza virus vaccines.

22 are poorly immunogenic compared to seasonal influenza virus vaccines.

23 ne candidates for the production of pandemic influenza virus vaccines.

24 ations for the design of novel modified live influenza virus vaccines.

25 can mount specific immune responses against influenza virus vaccines.

26 elopment of live species-specific attenuated influenza virus vaccines.

27 mutant influenza viruses as live attenuated influenza virus vaccines.

28 suggest its potential in development of live influenza virus vaccines.

29 the safety and efficacy in children of live influenza-virus vaccines.

30 anufacturing large quantities of inactivated influenza virus vaccine against potential pandemic strai

31 fluenza pandemic, it is important to prepare influenza virus vaccines against different subtypes and

32 as approved the expansion of live attenuated influenza virus vaccine and quadrivalent meningococcal c

33 live attenuated (LAIV) or inactivated (TIV) influenza virus vaccines and compared these to antibody

34 The preparation of live, attenuated human influenza virus vaccines and of large quantities of inac

35 hat the guinea pig model can be used to test influenza virus vaccines and that the efficiency of tran

36 essential for guiding design of "universal" influenza virus vaccines and therapeutics.

37 Current influenza virus vaccines are an effective prophylaxis ag

38 Current influenza virus vaccines are annually reformulated to el

39 a B virus infection.IMPORTANCE While current influenza virus vaccines are effective, they are affecte

40 The ability to use swine-origin influenza virus vaccines as a public health tool has bee

41 A universal influenza virus vaccine based on the same principles see

42 method for increasing the immunogenicity of influenza virus vaccines by exploiting the natural anti-

43 ve effectiveness of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) in children aged 18 mon

44 ramuscularly and trivalent live cold-adapted influenza virus vaccine (CAIV-T; n=1107) intranasally (i

45 Intranasal immunization with inactivated influenza virus vaccine can provide protective immunity,

46 The development of an H2 pandemic influenza virus vaccine candidate should therefore be co

47 PR/8/34 to rationally design live attenuated influenza virus vaccine candidates through genome-scale

48 BALB/c mice were nasally immunized with influenza virus vaccine combined with CT.

49 stalk-based chimeric hemagglutinin universal influenza virus vaccine constructs to protect against H7

50 Current influenza virus vaccines contain H1N1 (phylogenetic grou

51 The development of a universal influenza virus vaccine could abolish the need for this

52 n important consideration during "universal" influenza virus vaccine design.

53 A, including PIV5-NA, could improve seasonal influenza virus vaccine efficacy and provide protection

54 of the contribution of neuraminidase (NA) to influenza virus vaccine efficacy.

55 Influenza virus vaccine expressing alpha-Gal epitopes is

56 ve antibodies, immunization with inactivated influenza virus vaccines failed to do so in the mouse mo

57 An investigational live influenza virus vaccine, FluMist, contains three cold-ad

58 compatible polymer encapsulating inactivated influenza virus vaccine for insertion and dissolution in

59 Influenza virus vaccines have to be reformulated and rea

60 e immunity to vaccination with a T-dependent influenza virus vaccine; (ii) a CD4-independent pathway

61 ve the protective efficacy of an inactivated influenza virus vaccine in a neonatal mouse model.

62 targeted for the development of a universal influenza virus vaccine in humans.

63 results suggest that the efficacy of HA-DNA influenza virus vaccine in mice extends to chickens and

64 Despite the success of influenza virus vaccines in reducing severe illness, the

65 Vaccination with an inactivated influenza virus vaccine, in contrast, did not prevent gu

66 improve the efficacy of the current (killed) influenza virus vaccines include the generation of cold-

67 Live attenuated trivalent influenza virus vaccine induces expansion of CD8+ T cell

68 ome residents received inactivated trivalent influenza virus vaccine intramuscularly and simultaneous

69 We observed that when influenza virus vaccine is injected and an LT-IS patch i

70 Intramuscular administration of inactivated influenza virus vaccine is the main vaccine platform use

71 Inactivated influenza virus vaccines (IVVs) are used for prevention

72 The live attenuated influenza virus vaccine (LAIV) is preferentially recomme

73 esponses and, in the case of live-attenuated influenza virus vaccines (LAIV), there are safety concer

74 ate safer and more efficient live-attenuated influenza virus vaccines (LAIVs) based on recombinant vi

75 donor virus for FluMist, a live, attenuated, influenza virus vaccine licensed in 2003 in the United S

76 wed hope that the development of "universal" influenza virus vaccines may be within reach.

77 demonstrates efficacy in a variety of murine influenza virus vaccine models assaying homologous, hete

78 ern regarding the egg protein content in the influenza virus vaccine, pediatricians have in the past

79 rs of wild-type and pandemic live attenuated influenza virus vaccines (pLAIV) representing four subty

80 We vaccinated mice with formalin-inactivated influenza virus vaccine preparations containing disparat

81 Current influenza virus vaccines primarily aim to induce neutral

82 cacy in macaques of an intrarespiratory live influenza virus vaccine produced by truncating NS1 in th

83 This new system is thus suitable for influenza virus vaccine production and may be applicable

84 ale mortality and morbidity, but traditional influenza virus vaccine production is too slow for rapid

85 Current influenza virus vaccines protect mostly against homologo

86 Development of a universal influenza virus vaccine providing broadly cross-protecti

87 Currently licensed influenza virus vaccines rely on the antigenic match of

88 Current influenza virus vaccines rely upon the accurate predicti

89 We conclude that live attenuated pandemic influenza virus vaccines replicate similarly in AGMs and

90 r immunological parameters predict poor anti-influenza virus vaccine responses and can be used as bio

91 ansmissibility and systems-level analyses of influenza virus vaccine responses provide an improved fr

92 trates that inhibition of PA-X expression in influenza virus vaccine strains may provide a novel way

93 found poor lineage matches with recommended influenza virus vaccine strains.

94 irus hemagglutinin and stalk-based universal influenza virus vaccine strategies are being developed a

95 Current influenza virus vaccine strategies stimulate immune resp

96 rthermore, we recently developed a universal influenza virus vaccine strategy based on chimeric hemag

97 Immunization of ferrets by a universal influenza virus vaccine strategy based on viral vectors

98 oncept of a chimeric hemagglutinin universal influenza virus vaccine strategy that is based on the sa

99 lk domain has become a promising "universal" influenza virus vaccine strategy.

100 candidates could be developed into universal influenza virus vaccines that protect from infection wit

101 uman immunization with trivalent inactivated influenza virus vaccine (TIV) only rarely and modestly b

102 ound that the seasonal trivalent inactivated influenza virus vaccine (TIV) or a monovalent vaccine pr

103 ed by reassortment, can be used as safe live influenza virus vaccines to induce a long-lasting protec

104 icity and increase the protective breadth of influenza virus vaccines to reduce the seasonal disease

105 bjects received either trivalent inactivated influenza virus vaccine (TVV) intramuscularly and trival

106 Vaccination with the MF59-adjuvanted influenza virus vaccine was able to induce protective CD

107 rotein is the major immunogenic component in influenza virus vaccines, we sought to restore its expre

108 ctivated influenza virus, or live attenuated influenza virus vaccines were not protected against leth